Announcements Trials
Browse Landscape

Status

Available 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 247Observational 39Expanded_access 3

Sponsor

Cancer Type

Dermatologic 21Gastrointestinal 4Thoracic 3Gynecologic 3Genitourinary 3CNS 3Sarcoma 1Head & Neck 1Breast 1

Conditions

Ovarian Neoplasms 9Pancreatic Neoplasms 5Sarcoma 4Prostatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Melanoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 3Uterine Neoplasms 2Neoplasms 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Sarcoma, Ewing 1Primary Myelofibrosis 1PSR Ovarian Cancer With a BRCA Mutation 1Ovarian Diseases 1Osteosarcoma 1Neurofibrosarcoma 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1

Interventions

ulixertinib 1pegilodecakin 1balstilimab 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Melanoma × Gynecologic × Clear all
NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡